Fifth Third Rewards Shareholders With New Share Repurchase Program
Fifth Third Bancorp's FITB board of directors has approved a new share repurchase authorization of up to 100 million shares.
The new authorization replaces the previous authorization announced in June 2019, under which 11.8 million shares remained. The new repurchase authorization offers flexibility, allowing stock buybacks without a set expiration or price limit. The company may conduct repurchases through open-market transactions or privately negotiated transactions, including Rule 10b5-1 programs. The repurchase program may be modified, suspended, or discontinued at any time based on market conditions, legal requirements, and other uncertainties.
Fifth Third pays quarterly dividends regularly. In September 2024, the company announced a 5.7% increase in its quarterly dividend to 37 cents per share. Over the last five years, the company increased its quarterly dividend four times. It has a payout ratio of 44%.
Considering yesterday's closing price of $38.32, its annualized dividend yield is 3.86%.
Fifth Third Bancorp dividend-yield-ttm | Fifth Third Bancorp Quote
The company maintains a decent liquidity position. As of March 31, 2025, the company had cash and due from banks of $17.9 billion, while cash levels remain decent relative to total debt of $19.9 billion, with $5.5 billion in short-term borrowings. Further, as of March 31, 2025, Fifth Third's common equity tier (CET) 1 ratio was 10.45%. This offers room for the company to enhance its capital distribution plans.
Hence, a decent balance sheet position, along with its earnings strength, indicates that FITB's capital distributions are sustainable.
Shares of FITB have gained 6.2% compared with the industry's 17.8% growth over the past year.
Image Source: Zacks Investment Research
Currently, the company carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
In May 2025, MVB Financial Corp. MVBF authorized a $10 million stock repurchase program. The company plans to execute buybacks through open-market transactions, block trades, and privately negotiated deals.
With a strong liquidity position, holding $251 million in cash and cash equivalents, MVBF remains committed to enhancing shareholder value through capital distribution activities.
Likewise, in March 2025, KeyCorp KEY announced a $1 billion share repurchase plan, set to begin in the second half of the year. The company has not actively repurchased shares in recent years due to macroeconomic challenges, but is now taking steps to strengthen its capital ratios.
KEY raised its quarterly dividend by 5.1% to 20.5 cents per share in 2022 and has maintained that level since. While the company initially benefited from the Federal Reserve's rate hikes (which started in March 2022), rising funding and deposit costs later strained its financial and capital ratios.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fifth Third Bancorp (FITB) : Free Stock Analysis Report
KeyCorp (KEY) : Free Stock Analysis Report
Mvb Financial Corp. (MVBF) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Best Growth Stocks to Buy for June 20th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 20th: BAE Systems plc BAESY: This company that provides defense, aerospace, and security solutionscarries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.9% over the last 60 days. Bae Systems PLC price-consensus-chart | Bae Systems PLC Quote BAE has a PEG ratio of 1.95 compared with 3.47 for the industry. The company possesses a Growth Score of B. Bae Systems PLC peg-ratio-ttm | Bae Systems PLC Quote Intuit Inc. INTU: This financial management, compliance, and marketing products and services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.2% over the last 60 days. Intuit Inc. price-consensus-chart | Intuit Inc. Quote Intuit has a PEG ratio of 2.46 compared with 2.55 for the industry. The company possesses a Growth Score of A. Intuit Inc. peg-ratio-ttm | Intuit Inc. Quote Nova Ltd. NVMI: This process control systems company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.1% over the last 60 days. Nova Ltd. price-consensus-chart | Nova Ltd. Quote Nova has a PEG ratio of 1.88 compared with 9.79 for the industry. The company possesses a Growth Score of B. Nova Ltd. peg-ratio-ttm | Nova Ltd. Quote See the full list of top ranked stocks here. Learn more about the Growth score and how it is calculated here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuit Inc. (INTU) : Free Stock Analysis Report Bae Systems PLC (BAESY) : Free Stock Analysis Report Nova Ltd. (NVMI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
19 hours ago
- Yahoo
Here's Why Sony (SONY) Fell More Than Broader Market
Sony (SONY) closed at $24.75 in the latest trading session, marking a -4.37% move from the prior day. This move lagged the S&P 500's daily loss of 0.22%. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq decreased by 0.51%. The electronics and media company's shares have seen an increase of 2.17% over the last month, surpassing the Consumer Discretionary sector's loss of 0.1% and the S&P 500's gain of 0.45%. The investment community will be closely monitoring the performance of Sony in its forthcoming earnings report. On that day, Sony is projected to report earnings of $0.23 per share, which would represent a year-over-year decline of 4.17%. For the full year, the Zacks Consensus Estimates project earnings of $1.16 per share and a revenue of $79.87 billion, demonstrating changes of -5.69% and -6.09%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Sony. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.31% lower. Sony is currently a Zacks Rank #5 (Strong Sell). With respect to valuation, Sony is currently being traded at a Forward P/E ratio of 22.26. This signifies a discount in comparison to the average Forward P/E of 33.66 for its industry. Meanwhile, SONY's PEG ratio is currently 12.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. SONY's industry had an average PEG ratio of 12.44 as of yesterday's close. The Audio Video Production industry is part of the Consumer Discretionary sector. With its current Zacks Industry Rank of 193, this industry ranks in the bottom 22% of all industries, numbering over 250. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sony Corporation (SONY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
20 hours ago
- Business Wire
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited ('Verdiva' or 'the Company') a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva's investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions. 'These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies," said Dr. Mohamed Eid, CMO, Verdiva Bio Share 'Our first data presentation as Verdiva Bio at the prestigious ADA meeting marks a key milestone for our team. These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies,' stated Dr. Mohamed Eid, CMO at Verdiva. 'The early clinical and preclinical data not only show the potential of these compounds individually, but also the additive effect they may have in combination, highlighting the flexibility of our modular portfolio approach. At Verdiva Bio, we are committed to developing convenient, patient-friendly and commercially scalable therapeutic options for obesity, cardiometabolic disorders and related complications. We're excited about the potential of our once-weekly oral peptide candidates to help address this global health challenge.' VRB-101: An investigational once-weekly oral GLP-1 analog This presentation highlights new clinical pharmacokinetic data for VRB-101, an investigational, once-weekly, cAMP-biased oral GLP-1RA formulated with Verdiva's clinically validated, proprietary oral delivery technology T2026. Phase 1 results demonstrated that oral VRB-101 achieved drug levels comparable to, or exceeding, those of currently available once-weekly injectable GLP-1RA therapies. These findings support continued investigation of VRB-101 as a potential once-weekly, scalable oral therapeutic option for both weight reduction and long-term weight maintenance, with the potential to exert potent weight reduction and may improve adherence via a more patient-friendly dosing regimen. Poster Presentation #069 Title: VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center VRB-103: Efficacy of novel once-weekly oral amylin analog as a monotherapy, and in combination with VRB-101 in vivo A second presentation will share novel preclinical data on VRB-103, an investigational potentially once-weekly oral amylin analog, tested alone and in combination with VRB-101. In preclinical models, the rationally designed peptide combination showed an additive effect on body weight reduction. Additionally, co-formulation of these peptides in a single tablet with T2026 maintained comparable plasma exposure for both compounds. These data support continued development of VRB-103 as both a monotherapy and in combination with VRB-101. Poster Presentation #068 Title: Efficacy of a novel oral amylin analog and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center About Verdiva Bio Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva's most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit
